Tacrolimus is a 23-membered macrolide lactam natural product first isolated in 1987 by Kino and colleagues from the fermentation broth of Streptomyces tsukubaensis, a soil actinomycete discovered near Mount Tsukuba in Japan — the origin of the synonyms FK506, fujimycin and tsukubaenolide. Its structure features a hemiketal and a pipecolic acid moiety; the formula is C44H69NO12 with MW 804.02. It acts as a calcineurin inhibitor immunosuppressant and is marketed as Prograf and Advagraf (systemic) and Protopic (topical).

Both are calcineurin inhibitors, but they engage different immunophilins: tacrolimus binds FKBP12 while cyclosporine binds cyclophilin A. The classic Cell 1991 paper by Liu et al. showed that both drug–immunophilin complexes converge on the same target, calcineurin. Tacrolimus is 10–100 times more potent on a molar basis and is generally associated with lower acute rejection rates; KDIGO 2009 recommends it as the first-line CNI in kidney transplantation. Toxicity profiles differ: tacrolimus carries greater risk of post-transplant diabetes and neurotoxicity, while cyclosporine more often causes hirsutism, gingival hyperplasia and hyperlipidemia.

Systemic tacrolimus (oral capsules, extended-release tablets, or IV) produces whole-blood concentrations sufficient for organ-transplant immunosuppression and mandates therapeutic drug monitoring. Topical tacrolimus ointment relies on the fact that an 804 Da macrolide penetrates inflamed epidermis effectively but crosses into the systemic circulation only minimally. The result is potent local calcineurin inhibition in skin-resident T cells, mast cells and Langerhans cells with negligible systemic immunosuppression. A major advantage over topical corticosteroids is that tacrolimus does not cause skin atrophy, making it suitable for facial, periorbital and intertriginous areas.

Tacrolimus is metabolized by CYP3A4 and CYP3A5 in liver and intestine and is also a P-glycoprotein substrate. Carriers of at least one functional CYP3A5*1 allele ("expressers") clear tacrolimus considerably faster and typically require approximately 1.5–2× higher doses to reach the same trough target than CYP3A5*3/*3 non-expressers. Because expresser frequency differs markedly across ancestries, CYP3A5 is one of the best-validated examples of genotype-guided dosing, formalized in the CPIC guideline (2015).

Tacrolimus has a narrow therapeutic index coupled with extreme pharmacokinetic variability. Oral bioavailability averages about 24% but ranges from 5% to 67%, and half-life in transplant recipients averages ~11.3 hours with a range of 3.5–40.6 hours. Protein binding exceeds 98.8% and the drug partitions heavily into erythrocytes, so whole blood rather than plasma is the monitoring matrix. Under-exposure risks acute rejection; over-exposure causes nephrotoxicity, tremor and neurotoxicity, hyperkalemia and new-onset diabetes. Numerous CYP3A inhibitors (azole antifungals, macrolide antibiotics, diltiazem) and inducers (rifampin, carbamazepine) further mandate monitoring.

Tacrolimus is the standard chemical probe for the calcium–calcineurin–NFAT pathway. Because inhibition requires prior complexation with FKBP12, the compound offers an elegant "composite surface" mechanism that has become a paradigm in chemical biology. In practice, FK506 treatment cleanly prevents NFAT dephosphorylation and nuclear import, enabling researchers to attribute transcriptional changes to calcineurin activity in T-cell activation, cardiac hypertrophy, osteoclastogenesis, neuronal plasticity and tumor biology. Cyclosporine A is commonly used in parallel as an orthogonal immunophilin control.

Tacrolimus is practically insoluble in water and is a BCS Class 2 compound (LogP ~3.3). Prepare concentrated stocks in DMSO (>3 mg/mL); ethanol and acetone are also suitable. For cell assays, dilute the DMSO stock into media keeping final DMSO ≤0.1% v/v, and pre-warm to avoid precipitation. For in vivo work, DMSO/PEG300/Tween-80/saline or cremophor-based vehicles are commonly used. Store the solid at −20°C, sealed and dry, protected from light; aliquot stock solutions to avoid repeated freeze–thaw cycles.

Tacrolimus exhibits polymorphism, and the reported melting range of 113–133°C reflects different crystalline and amorphous solid forms. Commercial oral formulations typically use the amorphous solid dispersion to overcome poor aqueous solubility. Because solid-state form directly affects dissolution and bioavailability, polymorph characterization by DSC, XRPD and dissolution testing is a routine part of tacrolimus formulation and generic bioequivalence research.

Blocking NFAT-dependent transcription suppresses a broad cytokine program. In addition to IL-2, tacrolimus reduces TNF-α, IL-1β, IL-6, IL-3, IL-4, IFN-γ and GM-CSF, and it downregulates surface IL-2 receptor expression. It also inhibits mediator release from mast cells and basophils and reduces the antigen-presenting activity of Langerhans cells — effects that are particularly relevant to the efficacy of topical formulations in atopic dermatitis.

Every batch ships with a Certificate of Analysis (COA) including HPLC purity, NMR structural confirmation, and MS data. MSDS/SDS, residual solvent data, solubility datasheets, and Certificates of Origin are available on request. Sample evaluation is available for qualified institutions — please contact us for details.